Sharekhan's research report on Sun Pharmaceutical Industries
Strong quarterly performance; Numbers beat our as well as street’s expectations. Overall business growth guidance of double-digit teen growth with improvement in margins maintained.
Outlook
We maintain our Hold rating on the stock with an upward revised PT of Rs. 500. We expect the company to report a sales and profit CAGR of 20% and 38%, respectively, over FY2019-FY2021E.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!